In the recent High Court case determining whether the NHS is allowed to continue using Avastin rather than the far more expensive Lucentis (or the even more expensive alternative) one thought has repeatedly come to me.
In treatment for wet macular degeneration, the consultants have been very strongly behind making available an affordable and effective treatment. They can see the obvious, that using Lucentis would result in far fewer treatments being provided. Therefore, it is obviously in the interests of the population of patients that Avastin be used in preference to Lucentis.
When it comes to liothyronine, however, I really have not seen any support from endocrinology consultants for ensuring access to a less expensive source than UK licensed medicines. We all know that many endocrinology consultants are not persuaded that liothyronine (or any form of combination treatment) should be provided. However, even those who agree with using liothyronine do not appear to have lifted their little fingers towards ensuring that it really is made available. The most we have seen is semi-furtive advice to buy their own from Germany – and, if they are really lucky, a prescription that can be used to do so.
Of course, some endocrinology consultants might be working behind the scenes to this end. I’d like to know if they are. For now, unless I see contrary evidence, I shall just assume that we are being let down big time.